



**ASX / Media Release**

**14 June 2010**

---

## **FerriScan® Service selected for the UK Choose and Book System for GPs**

Resonance Health (ASX: RHT) is pleased to announce that the FerriScan service for quantifying iron overload has been made available through the National Health Service referral scheme 'Choose and Book'.

This scheme enables General Practitioners and Specialists across the UK to book patients for a FerriScan at participating hospitals. All UK doctors are able to go on-line and make an appointment while the patient is with them. The Whittington Hospital in London is the first participating hospital to provide the FerriScan service through the Choose and Book System, and Resonance Health is working to expand the number of participating hospitals.

This will better enable doctors to diagnose and manage the condition haemochromatosis, which is present in approximately 1 in 250 of the UK population. This condition causes the absorption of excessive iron from the diet, resulting in iron loading in major organs, primarily the liver.

While patients with other forms of iron overload are usually managed by specialist hematologists, patients with hereditary haemochromatosis are often managed by GPs and providing FerriScan access to these doctors opens a new market for FerriScan.

FerriScan is the core product of Resonance Health, providing an analysis of liver iron concentration to clinicians in over 20 countries worldwide. The FerriScan service has been endorsed by leading physicians and patient groups for the monitoring of patients suffering from transfusional iron overload disorders such as thalassaemia, sickle cell disease, Diamond Blackfan anaemia and myelodysplastic syndrome. It is now increasingly being used in iron-loading disorders such as haemochromatosis.

For further information please contact:

**Resonance Health**

Liza Dunne

Managing Director

T: + 61 8 9286 5300

E: lizad@resonancehealth.com

Eva O'Malley

Company Secretary

T + 61 8 9286 5300

E: evao@ferriscan.com

---

Resonance Health Ltd (ASX: RHT) ([www.resonancehealth.com](http://www.resonancehealth.com)) is a medical device company providing radiological image analysis services for the clinical and research communities. Its patented technology FerriScan provides a safe and accurate alternative for measuring liver iron concentration, a significant issue for patients with iron overload. The Company continues to invest in research and development into other quantitative radiological imaging technologies.